1. Home
  2. JOF vs RIGL Comparison

JOF vs RIGL Comparison

Compare JOF & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JOF
  • RIGL
  • Stock Information
  • Founded
  • JOF 1990
  • RIGL 1996
  • Country
  • JOF Japan
  • RIGL United States
  • Employees
  • JOF N/A
  • RIGL N/A
  • Industry
  • JOF Trusts Except Educational Religious and Charitable
  • RIGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • JOF Finance
  • RIGL Health Care
  • Exchange
  • JOF Nasdaq
  • RIGL Nasdaq
  • Market Cap
  • JOF 295.0M
  • RIGL 335.5M
  • IPO Year
  • JOF N/A
  • RIGL 2000
  • Fundamental
  • Price
  • JOF $10.87
  • RIGL $34.32
  • Analyst Decision
  • JOF
  • RIGL Buy
  • Analyst Count
  • JOF 0
  • RIGL 5
  • Target Price
  • JOF N/A
  • RIGL $38.20
  • AVG Volume (30 Days)
  • JOF 43.9K
  • RIGL 710.9K
  • Earning Date
  • JOF 01-01-0001
  • RIGL 11-06-2025
  • Dividend Yield
  • JOF 3.33%
  • RIGL N/A
  • EPS Growth
  • JOF N/A
  • RIGL N/A
  • EPS
  • JOF N/A
  • RIGL 5.43
  • Revenue
  • JOF N/A
  • RIGL $267,921,000.00
  • Revenue This Year
  • JOF N/A
  • RIGL $59.93
  • Revenue Next Year
  • JOF N/A
  • RIGL N/A
  • P/E Ratio
  • JOF N/A
  • RIGL $6.33
  • Revenue Growth
  • JOF N/A
  • RIGL 105.62
  • 52 Week Low
  • JOF $6.64
  • RIGL $13.37
  • 52 Week High
  • JOF $8.04
  • RIGL $43.72
  • Technical
  • Relative Strength Index (RSI)
  • JOF 66.50
  • RIGL 44.70
  • Support Level
  • JOF $10.77
  • RIGL $35.56
  • Resistance Level
  • JOF $10.95
  • RIGL $38.72
  • Average True Range (ATR)
  • JOF 0.11
  • RIGL 2.14
  • MACD
  • JOF -0.02
  • RIGL -1.19
  • Stochastic Oscillator
  • JOF 69.33
  • RIGL 5.84

About JOF Japan Smaller Capitalization Fund Inc

Japan Smaller Capitalization Fund Inc is a closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investments in smaller capitalization Japanese equity securities. Its portfolio of investments consists of different sectors such as banks, chemicals, construction, electric appliances, financing business, food, Information and Communication, Utilities, Real Estate, and others.

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Share on Social Networks: